AC Immune SA (ACIU) Revenue & Revenue Breakdown
AC Immune SA Revenue Highlights
Latest Revenue (Y)
$14.80M
AC Immune SA Revenue by Period
AC Immune SA Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $14.80M | 276.14% |
| 2022-12-31 | $3.94M | 100.00% |
| 2021-12-31 | - | -100.00% |
| 2020-12-31 | $15.43M | -86.10% |
| 2019-12-31 | $111.03M | 1443.31% |
| 2018-12-31 | $7.19M | -64.48% |
| 2017-12-31 | $20.25M | -12.75% |
| 2016-12-31 | $23.21M | -40.61% |
| 2015-12-31 | $39.09M | 29.14% |
| 2014-12-31 | $30.27M | - |
AC Immune SA generated $14.80M in revenue during NA 2023, up 276.14% compared to the previous quarter, and up 205.74% compared to the same period a year ago.
AC Immune SA Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $14.80M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | -100.00% |
| 2022-12-31 | $1.00K | -99.97% |
| 2022-09-30 | $3.93M | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | -100.00% |
| 2020-12-31 | $944.00K | -15.94% |
| 2020-09-30 | $1.12M | -12.13% |
| 2020-06-30 | $1.28M | -89.70% |
| 2020-03-31 | $12.41M | 1068.64% |
| 2019-12-31 | $1.06M | -96.82% |
| 2019-09-30 | $33.41M | 2111.18% |
| 2019-06-30 | $1.51M | -97.99% |
| 2019-03-31 | $75.04M | 5248.68% |
| 2018-12-31 | $1.40M | -39.13% |
| 2018-09-30 | $2.31M | 13.66% |
| 2018-06-30 | $2.03M | 39.09% |
| 2018-03-31 | $1.46M | -91.12% |
| 2017-12-31 | $16.42M | 1428.96% |
| 2017-09-30 | $1.07M | 42.63% |
| 2017-06-30 | $753.00K | -62.46% |
| 2017-03-31 | $2.01M | 40.28% |
| 2016-12-31 | $1.43M | 7.28% |
| 2016-09-30 | $1.33M | -93.32% |
| 2016-06-30 | $19.96M | 3999.38% |
| 2016-03-31 | $487.00K | 54.60% |
| 2015-12-31 | $315.00K | -98.71% |
| 2015-09-30 | $24.37M | 72.06% |
| 2015-06-30 | $14.17M | 5928.09% |
| 2015-03-31 | $235.00K | - |
AC Immune SA generated - in revenue during Q1 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
AC Immune SA Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RGNX | REGENXBIO | $90.24M | $22.30M |
| ACIU | AC Immune SA | $14.80M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| ABEO | Abeona Therapeutics | $3.50M | - |
| SYBX | Synlogic | $3.37M | $8.00K |
| FIXX | Q32 Bio | $1.16M | - |
| MNOV | MediciNova | $1.00M | - |
| BCEL | Atreca | $770.00K | $80.00K |
| OPT | Opthea | $108.41K | $61.27K |
| ANEB | Anebulo Pharmaceuticals | - | - |
| BDTX | Black Diamond Therapeutics | - | - |
| ANTX | AN2 Therapeutics | - | - |
| PHVS | Pharvaris | - | - |
| AVTE | Aerovate Therapeutics | - | - |
| GRTX | Galera Therapeutics | - | - |
| ELYM | Eliem Therapeutics | - | - |
| ACRV | Acrivon Therapeutics | - | - |
| PMVP | PMV Pharmaceuticals | - | - |
| FDMT | 4D Molecular Therapeutics | - | - |
| EFTR | eFFECTOR Therapeutics | - | - |
| IVVD | Invivyd | - | - |
| PEPG | PepGen | - | - |
ACIU Revenue FAQ
What is AC Immune SA’s yearly revenue?
AC Immune SA's yearly revenue for 2023 was $14.8M, representing an increase of 276.14% compared to 2022. The company's yearly revenue for 2022 was $3.94M, representing an increase of 100.00% compared to 2021. ACIU's yearly revenue for 2021 was $0, representing a decrease of -100.00% compared to 2020.
What is AC Immune SA’s quarterly revenue?
AC Immune SA's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $14.8M, a 100.00% increase from the previous quarter (Q3 2023), and a 1480000.00% increase year-over-year (Q4 2022). ACIU's quarterly revenue for Q3 2023 was $0, a 100.00% increase from the previous quarter (Q2 2023), and a -100.00% decrease year-over-year (Q3 2022).
What is AC Immune SA’s revenue growth rate?
AC Immune SA's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was -86.67%.